stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Total debt
Xenon Pharmaceuticals Inc.'s total debt at the end of fiscal 2022 was $10.4M, up 26.4% from $8.3M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $11.0M. Over the past ten years it has ranged from $3.3M (fiscal 2020) to $15.5M (fiscal 2019); the current reading is higher than 67% of that period. Xenon Pharmaceuticals Inc. ranks 239th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $10.4M | 26.38% |
| FY2021 | $8.3M | 149.08% |
| FY2020 | $3.3M | (78.67%) |
| FY2019 | $15.5M | 3.50% |
| FY2018 | $15.0M | 120.66% |
| FY2017 | $6.8M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $11.0M | (4.37%) |
| Jun 2023 | $11.5M | (1.04%) |
| Mar 2023 | $11.6M | 11.42% |
| Dec 2022 | $10.4M | 45.80% |
| 20 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | $250.7M |
| ABCL AbCellera Biologics Inc. compare | $81.0M |
| IRON Disc Medicine, Inc. compare | $59.3M |
| RLAY Relay Therapeutics, Inc. compare | $55.0M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $48.1M |
| TNGX Tango Therapeutics, Inc. compare | $39.5M |
| XENE Xenon Pharmaceuticals Inc. | $11.0M |
| PBLS Parabilis Medicines, Inc. compare | $6.8M |
| IOVA Iovance Biotherapeutics, Inc. compare | $1.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement